Novel psychoactive substances (NPS): Clinical and pharmacological issues

Pharmacology, Toxicology and Pharmaceutical Science

• Opiate 100%
• Cannabinoid 50%
• Phenethylamine Derivative 50%
• Clinical Pharmacology 50%
• Psychotomimetic 50%
• Tryptamine 50%
• Cathinone 50%
• 4 Aminobutyric Acid 50%
• 4 Aminobutyric Acid B Receptor Stimulating Agent 50%
• Phencyclidine 50%
• Piperazine Derivative 50%

Keyphrases

• Novel Psychoactive Substances 100%
• Health Professionals 18%
• Clinical Management 18%
• Training Health Professionals 9%
• Pharmacology 9%
• Cathinone Derivatives 9%
• Evidence-based 9%
• Clinical Treatment 9%
• Stimulants 9%
• GABAB Receptor Agonists 9%
• Treatment Strategy 9%
• Opiates 9%
• Psychedelics 9%
• Opioids 9%
• Management Strategy 9%
• Synthetic Cannabinoids 9%
• Phencyclidine 9%
• Performance-enhancing Drugs 9%
• Prescription Drugs 9%
• Electronic Markets 9%
• Rate of Change 9%
• Plant Herbs 9%
• Tryptamine Derivatives 9%
• Piperazine 9%
• Clinical Pharmacology 9%
• GABAA 9%
• Phenethylamines 9%
• Large Series 9%
• Psychopathological 9%
• Design Methodology 9%
• Image-enhancing Drugs 9%